Evaxion Reports Q1 2026 Results and Business Update

According to a GlobeNewswire press release filed by Evaxion A/S and reproduced by outlets including The Manila Times, Evaxion published a business update and first quarter 2026 financial results on May 7, 2026, and hosted a conference call and webcast at 14:30 CET / 08:30 ET. The announcement lists new experimental and clinical updates, organizational changes, and a statement on cash runway into the second half of 2027.

The press release reports new preclinical/clinical data showing 86% vaccine target recognition by the company's AI-Immunology platform in the personalized cancer vaccine candidate EVX-01 (GlobeNewswire, Manila Times). The release also notes an additional data set indicating the platform's scalability in glioblastoma and completion of a one-year extension of the EVX-01 phase 2 trial, which the company says paves the way for presentation of three-year clinical data in the second half of 2026 (GlobeNewswire). The release further reports presentation of potentially superior polio vaccine design concepts arising from the collaboration with The Gates Foundation (GlobeNewswire).

The announcement includes organizational moves: promotion of Birgitte R?n? to the dual role of Chief Scientific and Chief Operating Officer and the election of Jens Bitsch-N?rhave to the Board of Directors, per the press release (GlobeNewswire, Manila Times). The release includes a direct quote from CEO Helen Tayton-Martin: "We maintain strong operational momentum as we continue our work to consolidate our position as a leader in AI-based target discovery, drug design and development," (GlobeNewswire, Manila Times).

Industry-pattern observations: AI-driven immunology platforms that combine antigen prediction with experimental validation commonly report preliminary metric-based readouts such as target recognition rates to demonstrate model-to-biology translation. Comparable programs in the sector typically require multiple orthogonal validations before clinical efficacy signals emerge in randomized trials, and presentation of multi-year clinical follow-up data is an important milestone for assessing durability of immune responses.

For investors and practitioners tracking computational vaccine discovery, the reported 86% target recognition figure is a tangible model-performance claim that warrants scrutiny of methods and datasets. Publication-style disclosures or peer-reviewed validation are the usual next steps for assessing reproducibility. The mention of scalability in glioblastoma and collaboration with The Gates Foundation places the work within both oncology and global-health pipelines, but the release does not disclose detailed methods, sample sizes, or independent validation in this announcement (GlobeNewswire).

Observers should monitor the slide deck, conference call transcript, or subsequent scientific presentations for methodological details behind the 86% metric (sample size, assay type, validation cohort) and the glioblastoma scalability data. Watch for the timing and content of the three-year EVX-01 data presentation the company said could occur in H2 2026 and any peer-reviewed publications or conference abstracts that reproduce these findings. Also follow updates to the company's financial filings for an itemized cash position and planned milestones linked to the runway into H2 2027 (GlobeNewswire, MarketBeat).

All event details and numbers in this report are drawn from Evaxion's May 4-7, 2026 press filings and the May 7, 2026 business update reproduced via GlobeNewswire and secondary outlets including The Manila Times and MarketBeat.